Unicycive Therapeutics, Inc.
UNCY
$0.6379
$0.0081.27%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | 0.00 | 0.00 | 0.00 |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | 0.00 | 0.00 | 0.00 |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | 0.00 | 0.00 | 0.00 |
SG&A Expenses | 15.53M | 12.10M | 10.21M | 9.57M | 9.09M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 30.90M | 32.12M | 29.17M | 28.86M | 25.78M |
Operating Income | -30.90M | -32.12M | -29.17M | -28.86M | -25.78M |
Income Before Tax | -15.20M | -36.73M | -23.00M | -23.24M | -36.93M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -15.20 | -36.73 | -23.00 | -23.24 | -36.93 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -15.20M | -36.73M | -23.00M | -23.24M | -36.93M |
EBIT | -30.90M | -32.12M | -29.17M | -28.86M | -25.78M |
EBITDA | -30.88M | -32.10M | -29.15M | -28.84M | -25.76M |
EPS Basic | -0.17 | -0.78 | -0.80 | -0.88 | -1.26 |
Normalized Basic EPS | 0.01 | -0.37 | -0.38 | -0.44 | -0.76 |
EPS Diluted | -0.45 | -1.01 | -1.03 | -1.12 | -1.26 |
Normalized Diluted EPS | -0.09 | -0.47 | -0.48 | -0.53 | -0.76 |
Average Basic Shares Outstanding | 349.40M | 267.49M | 196.63M | 140.32M | 117.64M |
Average Diluted Shares Outstanding | 412.55M | 323.63M | 252.77M | 196.46M | 117.64M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -7.21% | -2.98% | -4.76% | -4.71% | -- |